Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) Equity Average (2016 - 2025)

Historic Equity Average for CorMedix (CRMD) over the last 12 years, with Q3 2025 value amounting to $297.4 million.

  • CorMedix's Equity Average rose 46699.82% to $297.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $297.4 million, marking a year-over-year increase of 46699.82%. This contributed to the annual value of $58.9 million for FY2022, which is 1012.58% up from last year.
  • As of Q3 2025, CorMedix's Equity Average stood at $297.4 million, which was up 46699.82% from $167.8 million recorded in Q2 2025.
  • Over the past 5 years, CorMedix's Equity Average peaked at $297.4 million during Q3 2025, and registered a low of $51.5 million during Q2 2023.
  • For the 5-year period, CorMedix's Equity Average averaged around $83.4 million, with its median value being $64.2 million (2021).
  • Per our database at Business Quant, CorMedix's Equity Average plummeted by 2263.37% in 2022 and then soared by 46699.82% in 2025.
  • CorMedix's Equity Average (Quarter) stood at $66.1 million in 2021, then decreased by 15.72% to $55.7 million in 2022, then grew by 18.75% to $66.1 million in 2023, then rose by 8.41% to $71.7 million in 2024, then soared by 314.84% to $297.4 million in 2025.
  • Its last three reported values are $297.4 million in Q3 2025, $167.8 million for Q2 2025, and $99.8 million during Q1 2025.